Pasithea Therapeutics CEO Resigns Without Stated Cause
Pasithea Therapeutics Corp. disclosed the immediate resignation of its chief executive officer in an SEC filing. The change leaves the biotech firm without a permanent CEO during ongoing clinical development efforts.
Michael Vadon / Wikimedia (CC BY-SA 4.0)Pasithea Therapeutics Corp. announced on May 4, 2026, that Dr. Tiago Reis Marques resigned as chief executive officer and director, effective immediately, according to the company's Form 8-K filed with the Securities and Exchange Commission.
The filing affects Pasithea's leadership structure, a Nasdaq-listed biotech company focused on developing treatments for psychiatric and neurological disorders. Pasithea reported $15.5 million in cash reserves as of its last quarterly filing, with clinical trials underway for its lead candidate PAS-004, targeting neurofibromatosis type 1, which impacts about 100,000 people in the U.S. per Centers for Disease Control and Prevention data.
Prior to the resignation, Dr. Marques served as CEO since the company's founding in 2020, overseeing research and development operations. The new state establishes an interim leadership period, with no successor named in the filing. The change took effect on May 4, 2026, as stated in Item 5.02 of the 8-K.
The resignation triggers a requirement under Nasdaq rules for Pasithea to appoint a new CEO within a reasonable period to maintain listing compliance. Item 7.01 of the filing includes a press release disclosing the change, which must be furnished to investors under Regulation FD.
Item 9.01 attaches the press release as an exhibit, initiating potential shareholder communications and proxy statement updates in subsequent filings.
Pasithea completed its initial public offering in September 2021, raising $36 million. The company last reported a director departure in a 2024 8-K filing, involving a board member's retirement.
Coverage spread
Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.
No mainstream coverage of this story has surfaced yet.
Transparency Panel
Related Stories
Jashuah / Wikimedia (CC BY-SA 3.0)Oil Prices Drop After Reports of U.S.-Iran Talks on Ending War and Reopening Strait of Hormuz
Oil prices dropped significantly following reports that the U.S. and Iran are close to a memorandum of understanding to halt fighting and begin nuclear talks. President Trump announced a pause in the U.S. naval escort operation in the Strait of Hormuz. Iran is expected to respond…
The U.S. Food and Drug Administration / Wikimedia (Public domain)FDA Withdraws Studies Supporting Safety of COVID and Shingles Vaccines
The U.S. Food and Drug Administration blocked the publication of research finding rare side effects from COVID and shingles vaccines. The studies were withdrawn due to broad conclusions not supported by data, amid broader efforts by the Trump administration to challenge vaccine r…
UAE Leaves OPEC After 60 Years of Membership, Reducing Group to 11 Producers
The United Arab Emirates departed the Organization of the Petroleum Exporting Countries on Tuesday, reducing the group's membership to 11 nations. OPEC members now account for about 33% of global crude oil output. The exit occurs amid high oil prices and the ongoing closure of th…